StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) shareholders

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)

Close on Nov 17, 2026Market cap $109.97MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
35M of 31M shares
Institutional holders
144
28 new, 27 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
3 buys · 3 sales
Net sold $8.77M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Rajeev Shah
Joint filing with RA Capital Management, L.P. (13.60%), Peter Kolchinsky (13.60%) and 1 more
4,265,10613.60%13D (active) amendmentNov 5, 2025
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (15.10%), Rajeev Shah (15.10%) and 1 more
4,260,60615.10%13D (active) amendmentMay 7, 2025
FMR LLC
Joint filing with Abigail P. Johnson (11.80%)
3,702,71811.80%13G (passive) amendmentDec 31, 2025
Alpha Wave Ventures GP, Ltd3,612,211–13G (passive)Mar 21, 2024
Matthew Porteus3,548,5296.10%13G (passive) amendmentDec 31, 2023
Tang Capital Partners, LP
Joint filing with Tang Capital Management, LLC (5.40%), Kevin Tang (5.40%)
3,117,8435.40%13G (passive)Jan 24, 2024
BML Investment Partners, L.P.2,110,7276.70%13G (passive)Nov 2, 2026
BlackRock, Inc.1,804,0995.80%13G (passive)Mar 31, 2026
BlackRock Portfolio Management LLC1,645,4895.20%13G (passive)Sep 30, 2026
Israel A. Englander
Joint filing with Millennium Management LLC (5.10%), Millennium Group Management LLC (5.10%)
1,603,5125.10%13G (passive)Jun 23, 2026
Squarepoint Ops LLC
Joint filing with Squarepoint Capital LLP (5.10%), Squarepoint Operations Private Limited (5.10%) and 2 more
1,593,2465.10%13G (passive)Apr 1, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of LENZValueChange% of portfolio
Ra Capital Management, L.P.4,178,82313.30%$23.74M–0.21%
Alpha Wave Global, LP3,612,21111.50%$20.52M–0.33%
FMR LLC3,558,90511.33%$20.21M−38,8790.00%
Versant Venture Management, LLC2,656,8888.46%$15.09M–9.28%
BlackRock, Inc.2,292,1217.30%$13.02M+315,2980.00%
Squarepoint Ops LLC1,747,0965.56%$9.92M+240,5970.01%
abrdn plc1,547,8834.93%$8.79M+391,7220.01%
Millennium Management LLC1,508,4784.80%$8.57M+639,2210.00%
Vanguard Capital Management LLC1,097,7553.49%$6.24M+56,5670.00%
72 Investment Holdings, LLC1,017,7513.24%$5.78M–11.57%
Blue Owl Capital Holdings LP756,7222.41%$4.30M+250,0000.65%
C WorldWide Group Holding A/S700,0002.23%$3.98M–0.10%
Geode Capital Management, LLC564,6621.80%$3.21M+40,0880.00%
Trexquant Investment LP497,5261.58%$2.83M+283,1180.02%
Marshall Wace, Llp493,0991.57%$2.80M+332,8350.00%
Qube Research & Technologies Ltd482,1951.53%$2.74MNew0.00%
Morgan Stanley472,9951.51%$2.69M−175,8530.00%
Primecap Management Co/Ca/472,2001.50%$2.68M–0.00%
Tang Capital Management LLC451,1141.44%$2.56M–0.12%
Alyeska Investment Group, L.P.438,8821.40%$2.49M−24,6130.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202614435M100.0%28 / 5934 / 275M3M
Q1 202614533M100.0%35 / 5728 / 487M8M
Q4 202516135M100.0%50 / 5333 / 5513M7M
Q3 202516629M92.8%57 / 6424 / 48M3M
Q2 202511325M78.8%24 / 5415 / 165M1M
Q1 202510521M67.1%24 / 3027 / 123M2M
Q4 20249420M63.2%24 / 3221 / 82M1M
Q3 20247819M59.6%23 / 2016 / 92M2M
Q2 20246519M60.2%19 / 266 / 93M0M
Q1 20245516M51.8%55 / 00 / 016M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

151 funds held LENZ in Q1 2026, 36% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of LENZValue% of fundAs of
Fidelity Growth Company Fund1,228,6333.91%$9.56M0.01%May 31, 2026
Vanguard Total Stock Market Index Fund819,6062.61%$4.66M0.00%Jun 30, 2026
iShares Russell 2000 ETF538,6481.71%$3.06M0.00%Jun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund406,4001.29%$2.15M0.03%Jul 31, 2026
Fidelity Series Growth Company Fund314,1001.00%$2.44M0.01%May 31, 2026
Fidelity Growth Company K6 Fund313,0561.00%$2.44M0.01%May 31, 2026
Vanguard Extended Market Index Fund253,1130.81%$1.44M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund225,7840.72%$1.20M0.00%Jul 31, 2026
iShares Biotechnology ETF193,0130.61%$1.10M0.01%Jun 30, 2026
iShares Russell 2000 Value ETF172,5500.55%$980.08K0.01%Jun 30, 2026
Schwab U.S. Small-Cap ETF104,0120.33%$809.21K0.00%May 31, 2026
Vanguard Russell 2000 Index Fund101,7920.32%$791.94K0.00%May 31, 2026
iShares Micro-Cap ETF68,9370.22%$391.56K0.03%Jun 30, 2026
Fidelity Extended Market Index Fund59,3410.19%$461.67K0.00%May 31, 2026
U.S. Small Cap Equity Fund56,2170.18%$297.95K0.03%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Evert B. SchimmelpenninkPresident, CEO and Secretary, Director77,2890.25%Mar 30, 2026
Daniel R. ChevallardChief Financial Officer12,8860.04%Nov 3, 2026
Marc OdrichChief Medical Officer99,5990.32%Jan 6, 2026
Shawn OlssonChief Commercial Officer4,7330.02%Jan 6, 2026
Shelley B. ThunenDirector––Jun 15, 2026
Kimberlee C. DrapkinDirector––Jun 15, 2026
James W. McCollumDirector631,0992.01%Jun 15, 2026
Zachary ScheinerDirector––Jun 15, 2026
RA Capital Nexus Fund II, L.P.Director164,7290.52%Jun 15, 2026
Frederic GuerardDirector––Jun 15, 2026
Jeffrey P. GeorgeDirector5,5920.02%Jun 15, 2026
Peter Kolchinsky10% owner––Nov 2, 2026
Capital Healthcare Fund LP RA10% owner––Nov 2, 2026
Ra Capital Management, L.P.10% owner57,5590.18%Nov 2, 2026
Rajeev M. Shah10% owner––Nov 2, 2026
Versant Ventures VII GP-GP, LLC10% owner2,623,8118.35%Oct 2, 2025
Versant Venture Capital VI, L.P.10% owner2,916,5379.28%Oct 2, 2025
Versant Ventures VI GP-GP, LLC10% owner2,364,6717.53%Oct 2, 2025
Versant Ventures VI GP, L.P.10% owner3,015,1879.60%Oct 2, 2025
Versant Vantage II, L.P.10% owner––Oct 2, 2025
Versant Vantage II GP, L.P.10% owner4,542,15014.46%Oct 2, 2025
Versant Vantage II GP-GP, LLC10% owner2,636,4788.39%Oct 2, 2025
Versant Venture Capital VII, L.P.10% owner1,598,7895.09%Oct 2, 2025
Versant Ventures VII GP, L.P.10% owner3,101,9449.87%Oct 2, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Ra Capital Management, L.P.
10% owner
Oct 29, 2026Sale−107,170$3.36$360.09K57,559
Ra Capital Management, L.P.
10% owner
Oct 29, 2026Sale−451,998$3.36$1.52M242,757
Ra Capital Management, L.P.
10% owner
Oct 29, 2026Sale−2,159,516$3.36$7.26M1,159,823
Evert B. Schimmelpennink
President, CEO and Secretary, Director
Mar 27, 2026Buy+28,089$8.95$251.40K77,289
Daniel R. Chevallard
Chief Financial Officer
Mar 27, 2026Buy+7,500$8.57$64.28K12,886
Jeffrey P. George
Director
Mar 27, 2026Buy+5,592$8.92$49.88K5,592
Shawn Olsson
Chief Commercial Officer
Nov 17, 2025Sale(10b5-1 plan)−5,788$26.37$152.63K4,733
Shawn Olsson
Chief Commercial Officer
Nov 17, 2025Sale(10b5-1 plan)−4,212$25.74$108.42K10,521
Shawn Olsson
Chief Commercial Officer
Nov 17, 2025Option exercise+10,000$2.08$20.80K14,733
James W. McCollum
Director
Nov 7, 2025Buy+10,500$22.79$239.30K10,500
Daniel R. Chevallard
Chief Financial Officer
Nov 7, 2025Buy+20$22.71$4543,208
Daniel R. Chevallard
Chief Financial Officer
Nov 7, 2025Buy+2,178$22.76$49.57K5,386
Versant Vantage II GP-GP, LLC
10% owner
Sep 30, 2025Sale−123$47.01$5.78K764,127
Versant Vantage II GP-GP, LLC
10% owner
Sep 30, 2025Sale−177$47.01$8.32K1,050,599
Versant Vantage II GP-GP, LLC
10% owner
Sep 30, 2025Sale−57,502$46.41$2.67M764,250
Versant Vantage II GP-GP, LLC
10% owner
Sep 30, 2025Sale−83,066$46.41$3.86M1,050,776
Versant Vantage II GP-GP, LLC
10% owner
Sep 30, 2025Sale−49,701$45.35$2.25M1,133,842
Versant Vantage II GP-GP, LLC
10% owner
Sep 30, 2025Sale−34,405$45.35$1.56M821,752
Versant Venture Capital VI, L.P.
10% owner
Sep 18, 2025Sale−40,907$43.00$1.76M1,183,811
Versant Venture Capital VI, L.P.
10% owner
Sep 18, 2025Sale−268$43.30$11.60K1,183,543
Versant Venture Capital VI, L.P.
10% owner
Sep 18, 2025Sale−20,148$43.00$866.36K856,289
Versant Venture Capital VI, L.P.
10% owner
Sep 18, 2025Sale−132$43.30$5.72K856,157
Versant Venture Capital VI, L.P.
10% owner
Sep 18, 2025Sale−24,370$41.59$1.01M876,437
Versant Venture Capital VI, L.P.
10% owner
Sep 18, 2025Sale−49,479$41.59$2.06M1,224,718
Versant Ventures VII GP, L.P.
10% owner
Aug 26, 2025Sale−21,661$38.97$844.13K902,514
Versant Ventures VII GP, L.P.
10% owner
Aug 26, 2025Sale−3,465$39.50$136.87K1,274,197
Versant Ventures VII GP, L.P.
10% owner
Aug 26, 2025Sale−1,707$39.50$67.43K900,807
Versant Ventures VII GP, L.P.
10% owner
Aug 26, 2025Sale−43,978$38.97$1.71M1,277,662
Versant Ventures VII GP, L.P.
10% owner
Aug 25, 2025Sale−2,149$39.92$85.79K1,321,640
Versant Ventures VII GP, L.P.
10% owner
Aug 25, 2025Sale−24,760$39.53$978.76K925,233
Versant Ventures VII GP, L.P.
10% owner
Aug 25, 2025Sale−50,270$39.53$1.99M1,323,789
Versant Ventures VII GP, L.P.
10% owner
Aug 25, 2025Sale−1,058$39.92$42.24K924,175
Versant Ventures VII GP, L.P.
10% owner
Aug 22, 2025Sale−10,076$40.03$403.34K952,802
Versant Ventures VII GP, L.P.
10% owner
Aug 22, 2025Sale−2,809$40.59$114.02K949,993
Versant Ventures VII GP, L.P.
10% owner
Aug 22, 2025Sale−5,668$40.59$230.06K1,374,059
Versant Ventures VII GP, L.P.
10% owner
Aug 22, 2025Sale−20,493$40.03$820.33K1,379,727
Versant Venture Capital VI, L.P.
10% owner
Aug 18, 2025Sale−30,628$38.56$1.18M1,400,220
Versant Venture Capital VI, L.P.
10% owner
Aug 18, 2025Sale−15,085$38.56$581.68K962,878
Versant Venture Capital VI, L.P.
10% owner
Aug 15, 2025Sale−145,051$39.50$5.73M1,430,848
Versant Venture Capital VI, L.P.
10% owner
Aug 15, 2025Sale−69,949$39.50$2.76M977,963
Versant Ventures VII GP-GP, LLC
10% owner
Jul 10, 2025Sale−191,376$34.00$6.51M1,575,899
Versant Vantage II GP-GP, LLC
10% owner
Jun 27, 2025Sale−200,000$30.47$6.09M1,767,275
Versant Ventures VI GP, L.P.
10% owner
Jun 20, 2025Sale−133,924$30.25$4.05M1,967,275
Versant Ventures VI GP, L.P.
10% owner
Jun 20, 2025Sale−100,877$30.35$3.06M1,047,912
Versant Ventures VI GP, L.P.
10% owner
Jun 18, 2025Sale−100,000$29.95$3.00M1,148,789
Versant Vantage II GP-GP, LLC
10% owner
Jun 10, 2025Sale−350,000$29.00$10.15M1,248,789
Shawn Olsson
Chief Commercial Officer
Apr 9, 2025Option exercise+1,400$2.08$2.91K4,733
Evert B. Schimmelpennink
President, CEO and Secretary, Director
Mar 7, 2025Option exercise+4,200$1.04$4.37K49,200
Shawn Olsson
Chief Commercial Officer
Dec 16, 2024Option exercise+3,333$2.08$6.93K3,333
Evert B. Schimmelpennink
President, CEO and Secretary, Director
Jul 22, 2024Option exercise+45,000$1.04$46.80K45,000
Daniel R. Chevallard
Chief Financial Officer
May 14, 2024Buy+3,188$15.68$49.99K3,188
James W. McCollum
Director
May 13, 2024Buy+31,332$15.99$501.00K525,565
James W. McCollum
Director
Mar 21, 2024Award+16,633$15.03$249.99K494,233
James W. McCollum
Director
Mar 21, 2024Award+477,600––477,600
James W. McCollum
Director
Mar 21, 2024Award+95,034––95,034
Marc Odrich
Chief Medical Officer
Mar 21, 2024Award+99,599––99,599
Versant Vantage II GP, L.P.
10% owner
Mar 21, 2024Other+598,203––842,162
RA Capital Nexus Fund II, L.P.
Director, 10% owner
Mar 21, 2024Award+164,729––164,729
RA Capital Nexus Fund II, L.P.
Director, 10% owner
Mar 21, 2024Award+694,755––694,755
RA Capital Nexus Fund II, L.P.
Director, 10% owner
Mar 21, 2024Award+2,386,301––2,386,301

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
24.13%
7M shares short
Days to cover
5.6
At 1M shares a day
Change since last report
-22.3%
From 9M shares
Short volume, 20 days
36.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of LENZ Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 76,786 shares on Sep 23, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Shawn Olsson
Officer
Nov 17, 202540,000$1.02MNov 17, 2025Exercise of Stock Options

See a number that looks wrong?